Trial reportClinical and experimental immunology2003
IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin.
Trial report in Clinical and experimental immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 105 citations in OpenAlex.
- Current and emerging new approach & methodologies for skin hazard assessment.Toxicological research · 2026Review
- Review
- Participation of Hepcidins in the Inflammatory Response Triggered by λ-Carrageenin in Gilthead Seabream (Sparus aurata).Marine biotechnology (New York, N.Y.) · 2024Article
- Induction of IL-1β and antimicrobial peptides as a potential mechanism for topical dithranol.Experimental dermatology · 2021Article
- An IRF1-IRF4 Toggle-Switch Controls Tolerogenic and Immunogenic Transcriptional Programming in Human Langerhans Cells.Frontiers in immunology · 2021Article
- In vivo evaluation of the toxicity, genotoxicity, histopathological, and anti-inflammatory effects of the purified bioglycerol byproduct in biodiesel industry.Journal, genetic engineering & biotechnology · 2020Article
- Genomic programming of IRF4-expressing human Langerhans cells.Nature communications · 2020Article
- Interleukin-1 as Innate Mediator of T Cell Immunity.Frontiers in immunology · 2020Review
- Lower levels of interleukin-1β gene expression are associated with impaired Langerhans' cell migration in aged human skin.Immunology · 2018Article
- Lipopolysaccharide-Activated Leukocytes Enhance Thymic Stromal Lymphopoietin Production in a Mouse Air-Pouch-Type Inflammation Model.Inflammation · 2016Article
- Renoprotective Effect of Lactoferrin against Chromium-Induced Acute Kidney Injury in Rats: Involvement of IL-18 and IGF-1 Inhibition.PloS one · 2016Article
- Bone Regeneration Is Promoted by Orally Administered Bovine Lactoferrin in a Rabbit Tibial Distraction Osteogenesis Model.Clinical orthopaedics and related research · 2015Article
- Multifunctional iron bound lactoferrin and nanomedicinal approaches to enhance its bioactive functions.Molecules (Basel, Switzerland) · 2015Review
- Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.Cell communication and signaling : CCS · 2015Review
- Brugia malayi infective larvae fail to activate Langerhans cells and dermal dendritic cells in human skin.Parasite immunology · 2015Article
- Skin sensitization induced Langerhans' cell mobilization: variable requirements for tumour necrosis factor-α.Immunology · 2015Article
- Treatment-related restoration of Langerhans cell migration in psoriasis.The Journal of investigative dermatology · 2014Article
- Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma.Human vaccines & immunotherapeutics · 2014Article
- Lactoferrin modulation of BCG-infected dendritic cell functions.International immunology · 2009Article
- Lactoferrin as a natural immune modulator.Current pharmaceutical design · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In mice, the roles of cytokines in the initiation of epidermal Langerhans' cell (LC) migration are well documented; however, the mechanism of this response in humans is less well defined. The purpose of the present investigation was to examine the contribution of interleukin (IL)-1beta to human epidermal LC migration and to define further the mechanisms of this response. We demonstrate here that homologous recombinant IL-1beta administered intradermally to healthy human volunteers provides a stimulus for LC migration, with significant (P < 0.01) reductions in LC densities being observed at both 2 h and 4 h following treatment. At the later time-point of 4 h, injection of IL-1beta was also accompanied by activation of those LC remaining in the epidermis. Analysis of fluid aspirated from suction blisters formed at injection sites revealed significant (P < 0.01) tumour necrosis factor (TNF)-alpha production (2.99 +/- 1.18 pg TNF-alpha/mg protein; mean +/- s.d. of n = 10) in response to IL-1beta treatment compared with saline control injections (0.90 +/- 1.05 pg TNF-alpha/mg protein). Prior topical application of human recombinant lactoferrin (LF), an iron-binding protein found in exocrine secretions and skin, inhibited IL-1beta-mediated LC migration and also compromised the production of TNF-alpha protein as measured in suction blister fluids derived from each of the treatment sites. Taken together, these data demonstrate that IL-1beta is associated with both the stimulation of human epidermal LC migration and local TNF-alpha production. Topical treatment with LF compromises both these responses. These data suggest that topical LF may potentially represent a novel therapeutic in the treatment of skin inflammation where TNF-alpha is an important mediator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.